Duloxetine
Product Images NDC 64725-0747

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 64725-0747). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (64725 0747)

Label for Duloxetine Delayed-Release 30 mg capsules, indicating prescription use only. The label shows repackaging by TYA Pharmaceuticals in Tallahassee, Florida, with manufacturer listed as Laboratorios Dr Este. The label includes placeholder text for lot and expiration dates, a barcode, and a notice to see package insert for dosing information.*

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of the active ingredient in Duloxetine Delayed-Release, showing a molecular diagram with aromatic rings, thiophene, and an amine hydrochloride group.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph showing the percentage of patients improved plotted against the percent improvement in pain from baseline. The graph compares four groups: CYM 60mg BID, CYM 60mg QD, CYM 20mg QD, and placebo, indicating varying degrees of pain improvement among the groups over a range from 0 to 100 percent.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: CYM 60mg BID, CYM 60mg QD, and Placebo. The Y-axis represents percentage of patients improved, and the X-axis shows percent improvement in pain. The graph displays decreasing improvement percentages as pain improvement increases.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF) between placebo and CYM60/120 mg once daily. The graph shows two lines, one dotted for placebo and one solid for CYM60/120 mg, depicting the relative patient improvement across various pain improvement percentages from 0 to 100%.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows two lines representing the placebo group and the CYM60 mg once daily group, illustrating patient response rates at various improvement thresholds.*

FDA Label Image

Figure 5 (Duloxetine 06)

Line graph showing percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares Placebo and CYM 60/120 mg once daily groups, illustrating trends in patient improvement across varying pain improvement percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.